Boston Scientific Corporation (NYSE:BSX) Receives Average Recommendation of “Moderate Buy” from Analysts

Boston Scientific Corporation (NYSE:BSX) has been given a consensus rating of “Moderate Buy” by the twenty-four analysts that are covering the stock, Marketbeat.com reports. Three research analysts have rated the stock with a hold recommendation, twenty have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among analysts that have covered the stock in the last year is $109.4348.

Several equities analysts have weighed in on BSX shares. Oppenheimer lowered their price objective on shares of Boston Scientific from $125.00 to $100.00 and set an “outperform” rating on the stock in a research report on Friday, January 16th. Morgan Stanley lowered their price target on Boston Scientific from $130.00 to $118.00 and set an “overweight” rating on the stock in a report on Thursday, February 5th. Mizuho reduced their price objective on Boston Scientific from $140.00 to $115.00 and set an “outperform” rating for the company in a research note on Thursday, February 5th. Royal Bank Of Canada lowered their target price on Boston Scientific from $130.00 to $115.00 and set an “outperform” rating on the stock in a research note on Thursday, February 5th. Finally, Wells Fargo & Company dropped their target price on Boston Scientific from $125.00 to $94.00 and set an “overweight” rating on the stock in a report on Thursday, February 5th.

Insider Activity at Boston Scientific

In other news, CEO Michael F. Mahoney sold 160,901 shares of the company’s stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total value of $15,042,634.49. Following the transaction, the chief executive officer directly owned 1,411,735 shares of the company’s stock, valued at approximately $131,983,105.15. This represents a 10.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Arthur C. Butcher sold 17,313 shares of Boston Scientific stock in a transaction on Monday, December 1st. The shares were sold at an average price of $101.55, for a total value of $1,758,135.15. Following the sale, the executive vice president directly owned 23,600 shares of the company’s stock, valued at approximately $2,396,580. The trade was a 42.32% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.50% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Boston Scientific

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. State Street Corp increased its stake in Boston Scientific by 1.1% in the 2nd quarter. State Street Corp now owns 65,191,864 shares of the medical equipment provider’s stock valued at $7,002,258,000 after buying an additional 713,379 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Boston Scientific by 0.8% in the third quarter. Vanguard Group Inc. now owns 138,249,447 shares of the medical equipment provider’s stock valued at $13,497,294,000 after acquiring an additional 1,115,337 shares during the last quarter. Synergy Asset Management LLC increased its position in shares of Boston Scientific by 3,493.0% in the third quarter. Synergy Asset Management LLC now owns 493,323 shares of the medical equipment provider’s stock valued at $48,297,000 after acquiring an additional 479,593 shares during the last quarter. Gladstone Institutional Advisory LLC raised its holdings in Boston Scientific by 39.5% during the third quarter. Gladstone Institutional Advisory LLC now owns 51,884 shares of the medical equipment provider’s stock worth $5,065,000 after acquiring an additional 14,700 shares in the last quarter. Finally, Channel Wealth LLC boosted its position in Boston Scientific by 70.8% during the third quarter. Channel Wealth LLC now owns 28,577 shares of the medical equipment provider’s stock valued at $2,790,000 after purchasing an additional 11,847 shares during the last quarter. 89.07% of the stock is owned by hedge funds and other institutional investors.

Boston Scientific Trading Up 0.8%

Boston Scientific stock opened at $74.72 on Tuesday. The firm has a market cap of $110.76 billion, a price-to-earnings ratio of 38.51, a price-to-earnings-growth ratio of 1.03 and a beta of 0.67. Boston Scientific has a 1 year low of $72.69 and a 1 year high of $109.50. The firm’s 50 day moving average price is $90.56 and its two-hundred day moving average price is $97.35. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.96 and a current ratio of 1.51.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, topping analysts’ consensus estimates of $0.78 by $0.02. Boston Scientific had a return on equity of 19.96% and a net margin of 14.44%.The firm had revenue of $5.29 billion for the quarter, compared to analysts’ expectations of $5.29 billion. During the same quarter last year, the business posted $0.70 EPS. Boston Scientific’s revenue was up 15.9% on a year-over-year basis. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. On average, research analysts predict that Boston Scientific will post 2.85 EPS for the current fiscal year.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.